Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Currently amended). A tumor cell transfected with a DNA coding for at least one MHC class II ligand selected from the group consisting of LAG-3, and a derivative thereof that maintains the ability to bind the MHC Class II molecules which bind LAG-3, wherein said LAG-3 derivative is a mutant or a soluble fragment of LAG-3 selected from the group consisting of a soluble fragment of LAG-3 consisting of at least one of the four immunoglobulin extracellular domains, a fragment of LAG-3 consisting of the extracellular domains D1 and D2, a fragment of LAG-3 consisting of the four immunoglobulin extracellular domains, and a mutant form of a soluble LAG-3 comprising the extracellular domains D1 and D2, said mutant being defined by one or more amino acid substitutions selected from the group consisting of:

Arg at residue position 73 substituted with Glu;

Arg at residue position 75 substituted with Ala;

Arg at residue position 75 substituted with Glu; and

Arg at residue position 76 substituted with Glu.

Claim 2 (Cancelled).

3(Currently amended). A process for preparing the tumor cell of claim 1, comprising:

removing tumor cells from a patient;

transfecting a tumor cell with a DNA coding for at least one MHC class II ligand selected from the group consisting of LAG-3, and a derivative thereof that maintains the ability to bind the MHC Class II molecules which bind LAG-3, wherein said LAG-3 derivative is a mutant or a soluble fragment of LAG-3 selected from the group consisting of a soluble fragment of LAG-3 consisting of at least one of the four immunoglobulin extracellular domains, a fragment of LAG-3 consisting of the extracellular domains D1 and D2, a fragment of LAG-3 consisting of the four immunoglobulin extracellular domains, a mutant form of a soluble LAG-3 comprising the extracellular domains D1 and D2, said mutant defined by one or more amino acid substitutions selected from the group consisting of

Arg at residue position 73 substituted with Glu;

Arg at residue position 75 substituted with Ala;

Arg at residue position 75 substituted with Glu; and

Arg at residue position 76 substituted with Glu; and

recovering the transfected tumor cell.

Claims 4-6 (Cancelled).

7(Currently amended). A pharmaceutical composition for treating pathological conditions involving an antigen specific immune response, comprising a pharmaceutically acceptable vehicle and cells transfected with DNA coding for at least one MHC class II ligand selected from the group consisting of LAG-3 and a derivative thereof and expressing [[LAG-3]] said at least one MHC class II ligand, wherein said LAG-3 derivative maintains the ability to bind the MHC Class II molecules which bind LAG-3 and is a mutant or a soluble

fragment of LAG-3 selected from the group consisting of a soluble fragment of LAG-3 consisting of at least one of the four immunoglobulin extracellular domains, a fragment of LAG-3 consisting of the extracellular domains D1 and D2, a fragment of LAG-3 consisting of the four immunoglobulin extracellular domains, a mutant form of a soluble LAG-3 comprising the extracellular domains D1 and D2, said mutant being defined by one or more amino acid substitutions selected from the group consisting of:

Arg at residue position 73 substituted with Glu;

Arg at residue position 75 substituted with Ala;

Arg at residue position 75 substituted with Glu; and

Arg at residue position 76 substituted with Glu.

Claim 8 (Cancelled).

9(Previously presented). A method for treating a pathological condition involving antigen specific T-cell mediated immune response, comprising administering the pharmaceutical composition of claim 7 to a subject in need thereof.

Claims 10 and 11 (Cancelled).

12(Previously amended). A pharmaceutical composition according to claim 7, wherein said cells are tumor cells.